Blackrock Health Sciences Term Trust

BlackRock Health Sciences Term Trust's Portfolio Manager, Liu Xiang, reported vesting and cash settlement of phantom shares.

BlackRock Health Sciences Term Trust portfolio manager, Xie H Erin, reported the sale of common stock following the vesting and conversion of phantom shares.

A director at BlackRock Health Sciences Term Trust executed pre-planned sales of common stock totaling over 20,000 shares in December 2025.

Saba Capital Management, L.P. reports disposition of shares in BlackRock Health Sciences Term Trust (BMEZ) due to a change of control transaction.

Portfolio Manager Erin Xie H reports the acquisition and disposal of common stock and phantom shares in BlackRock Health Sciences Term Trust on January 31, 2025.

Portfolio Manager Kyle McClements reports acquisition and disposal of BlackRock Health Sciences Term Trust (BMEZ) common stock and phantom shares on January 31, 2025.

BlackRock's closed-end funds are holding a joint virtual annual meeting on July 22, 2026, to elect nominees to their Boards of Directors/Trustees.

BlackRock Closed-End Funds will hold a virtual joint annual meeting of shareholders on July 11, 2025, to vote on the election of board nominees.

BlackRock urges shareholders to vote in favor of its board nominees and against a proposal by Saba Capital to terminate BlackRock as investment manager, highlighting the fund's performance and discount management program.

Glass Lewis recommends voting for BlackRock's board nominees and against Saba Capital's proposals to terminate BlackRock as investment adviser for ten closed-end funds.

BlackRock Health Sciences Term Trust files a definitive proxy statement with the Securities and Exchange Commission.

Institutional Shareholder Services (ISS) recommends shareholders vote against Saba Capital's proposals to terminate BlackRock as investment adviser for multiple closed-end funds and supports BlackRock's board nominees.

BlackRock Health Sciences Term Trust (BMEZ) has agreed to a cash tender offer to repurchase 40% of its outstanding common shares at 99.5% of net asset value, settling a dispute with activist investor Saba Capital Management, L.P., which will tender its shares and abide by a three-year standstill agreement.